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Gene-panel sequencing allows comprehensive analysis of multiple genes simultaneously and is
now routinely used in clinical mutation testing of high-risk breast and ovarian cancer patients.
However, only BRCA1 and BRCA2 are often analyzed also for large genomic changes. Here, we
have analyzed 10 clinically relevant susceptibility genes in 95 breast or ovarian cancer patients
with gene-panel sequencing including also copy number variants (CNV) analysis for genomic
changes. We identified 12 different pathogenic BRCA1, BRCA2, TP53, PTEN, CHEK2, or
RAD51C mutations in 18 of 95 patients (19%). BRCA1/2 mutations were observed in 8 patients
(8.4%) and CHEK2 protein-truncating mutations in 7 patients (7.4%). In addition, we identified a
novel duplication encompassing most of the RAD51C gene. We further genotyped the duplica-
tion in breast or ovarian cancer families (n = 1149), in unselected breast (n = 1729) and ovarian
cancer cohorts (n = 553), and in population controls (n = 1273). Seven additional duplication
carries were observed among cases but none among controls. The duplication associated with
ovarian cancer risk (3/590 of all ovarian cancer patients, 0.5%, P = .032 compared with con-
trols) and was found to represent a large fraction of all identified RAD51C mutations in the
Finnish population. Our data emphasizes the importance of comprehensive mutation analysis
including CNV detection in all the relevant genes.
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1 | INTRODUCTION
Most of the familial risk of breast and ovarian cancer is still unex-
plained. The majority of the known predisposing mutations are in
genes that function in DNA damage response and DNA repair. The
most important breast and ovarian cancer susceptibility genes are
BRCA1 (OMIM *113705) and BRCA2 (OMIM *600185) conferring
on average 60% and 55% cumulative risks of breast cancer by the
age of 70 and 59% and 16.5% risk of ovarian cancer, respectively.1
Mutations in the other high-risk genes TP53 (OMIM *191170),
PTEN (OMIM *601728), STK11 (OMIM *602216), and CDH1
(OMIM *192090) confer an increased risk of breast cancer in the
context of rare hereditary cancer-predisposition syndromes.2–6
Mutations in CHEK2 (OMIM *604373) and PALB2 (OMIM
*610355) confer a more moderate risk of breast cancer while
mutations in RAD51C (OMIM *602774) and RAD51D (OMIM
*602954) increase the risk of ovarian cancer.7–10 In addition, a
large number of common low-risk breast and ovarian cancer var-
iants have been identified.11,12 In the Finnish population, the major-
ity of the mutations that have been observed in BRCA1, BRCA2,
CHEK2, PALB2, RAD51C, and RAD51D are recurrent founder
mutations.13–17
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In the past, clinical genetic testing of high-risk individuals, for
example familial or early-onset breast cancer cases, was mainly lim-
ited to the BRCA1 and BRCA2 genes. Since the development of next-
generation sequencing techniques, multigene panel testing has been
increasingly utilized. Several studies have reported approximately 4%
to 6% frequency of mutations in genes other than BRCA1/2 among
hereditary breast and ovarian cancer patients.18 If only BRCA1/2 test-
ing was performed, a large number of patients with potentially
actionable mutations would not receive a molecular diagnosis. Fur-
thermore, single-gene tests are not comprehensive as more than 1 risk
variants may be segregating in some cancer families and thus a nega-
tive test result for a single gene would not be enough for risk stratifi-
cation. The downside is that the commercially available gene-panels
include a vast range of known and putative breast cancer susceptibil-
ity genes of which only some have clinical utility.19 Some panels also
include a broad range of cancer predisposition genes that may
increase the risk of other malignancies but not breast cancer. Easton
et al estimated that currently only BRCA1, BRCA2, TP53, CDH1, PTEN,
STK11, NF1, PALB2, CHEK2, ATM, and NBN have sufficient evidence
of association with breast cancer to have clinical validity and utility.19
In addition to these genes, there is clear evidence of association with
ovarian cancer for mutations in RAD51C, RAD51D, and BRIP1 but the
association with breast cancer is uncertain.9,10,19,20
Here, we have analyzed the BRCA1, BRCA2, CDH1, PTEN, STK11,
TP53, CHEK2, PALB2, RAD51C, and RAD51D genes in 95 high-risk
breast or ovarian cancer patients by gene-panel sequencing. We iden-
tified a novel RAD51C germline duplication which was further charac-
terized for breast and ovarian cancer risk by screening the duplication
in Finnish familial and unselected breast and ovarian cancer patients.
We also performed expression analysis for RAD51C duplication car-
riers and non-carriers.
2 | MATERIALS AND METHODS
2.1 | Subjects
Gene-panel sequencing was performed for germline DNA samples of
95 unrelated breast or ovarian cancer patients ascertained at the Hel-
sinki University Hospital Department of Clinical Genetics. The
patients referred to genetic testing fulfilled the following criteria: at
least 3 breast or ovarian cancer cases among first- or second-degree
relatives including the proband (n = 35), 2 breast or ovarian cancer
cases among first-degree relatives including the proband (n = 23),
male breast cancer (n = 5), early-onset breast cancer cases diagnosed
with breast cancer at the age of 40 or younger (n = 18), triple-
negative breast cancer cases (TNBC, ie, estrogen receptor [ER], pro-
gesterone receptor [PR] and HER2 negative) diagnosed at the age of
50 or younger (n = 10), patients diagnosed with both breast and
ovarian cancer with a family history of other cancers (n = 3), and a
patient diagnosed with breast and colorectal cancer with family his-
tory of other cancers (n = 1). Information on family history of cancer
was collected from patient interviews thereafter most of the cancer
cases were verified from clinical records. Male relatives were
excluded when calculating the degree of relationship for the breast
cancer families. BRCA1/2 screening had been previously performed
for 17 patients with 13 patients screened negative for the Finnish
founder mutations and 4 patients for the full genes. In addition,
2 patients had a family member previously screened negative for the
full BRCA1/2 genes and 1 patient had a family member previously
screened negative for the BRCA1/2 founder mutations, these family
members were not tested with the gene-panel.
The identified RAD51C duplication was further genotyped in
1149 BRCA1/2-negative familial breast or ovarian cancer patients
(including 1122 breast cancer patients, 19 patients with both breast
and ovarian cancer, and 8 ovarian cancer patients), in 1729 unselected
breast cancer patients, and in 553 unselected ovarian cancer patients
ascertained at the Helsinki University Hospital as well as in 1273
healthy female population controls. Of the familial patients, 381 are
included also in the unselected breast cancer cohort, 3 in the unsel-
ected ovarian cancer cohort, and 2 in both the unselected breast and
unselected ovarian cancer cohorts. The patient cohorts are described
in more detail in the Supporting Information, Appendix S1. The sam-
ples from the unselected breast cancer patients and breast and ovarian
cancer families were germline DNA isolated from peripheral blood
whereas 429 samples from the unselected ovarian cancer patients
were genomic DNA and 124 were tumor DNA. Informed consent was
obtained from all individual participants and the study was approved
by the Ethics committee of the Helsinki University Hospital.
2.2 | Gene-panel sequencing
Ten genes (BRCA1, BRCA2, CDH1, CHEK2, PTEN, STK11, TP53, PALB2,
RAD51C, and RAD51D) included in a gene-panel, were analyzed in this
study. The SureSelectXT Custom 3-5.9 Mb library kit (Agilent Tech-
nology, Santa Clara, CA, USA) was used for DNA capture and the
sequencing was performed on the Illumina HiSeq 2500 (Illumina, San
Diego, CA, USA; Appendix S1). Identified variants were annotated for
their effect on protein coding transcripts and only protein-truncating
mutations (ie, nonsense, splicing and frameshift indel mutations) and
pathogenic missenses in the 10 studied genes were considered in this
study. Copy number variants (CNVs) were identified using an in-house
method based on the number of read pairs in short windows over the
target regions as described in the Appendix S1. In addition, BRCA1 and
BRCA2 large genomic changes were investigated by multiplex ligation-
dependent probe amplification (MLPA). Pathogenic mutations in the
studied genes were verified with Sanger sequencing.
2.3 | Duplication characterization
In the CNV analysis, a novel duplication covering the RAD51C exons
1 to 7 was identified. The exact size and location of the duplication
was characterized with polymerase chain reaction (PCR) in a germline
DNA sample of the carrier patient. The DNA was amplified using a
forward primer 50-CTGATCGTGCAGTTTGGGTC-30 that binds to
RAD51C intron 7 upstream of the duplication breakpoint and a
reverse primer 50-TTTTCTCGGCACCAAACCTT-30 that binds to the
duplicated sequence at the intergenic region upstream of RAD51C.
The PCR products were Sanger sequenced as described in Appen-
dix S1.
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2.4 | Genotyping
Relatives of the index patient with available DNA samples and the unsel-
ected and familial breast and ovarian cancer cohorts and population con-
trols were screened for the duplication with PCR assay. DNA samples
were amplified using the same primer pair as in duplication characteriza-
tion. A second reverse primer 50-AGGGGGAGGATTTACCAGTC-30 that
binds to RAD51C intron 7 in the non-duplicated region was used as a
control to monitor the success of the PCR reaction. The PCR products
were run on a 2% agarose gel. Samples containing the duplication dis-
played 2 bands on the gel and samples without the duplication 1 band
(Figure S1). All carriers were confirmed with a second PCR.
2.5 | Gene-expression analysis
Lymphoblastoid cell lines of 4 female breast cancer patients from the
index family, including 3 duplication carriers and 1 non-carrier, as well as
of 1 healthy, unrelated non-carrier woman were used for gene-expression
analysis. Gene-expression analysis was performed with Cells-to-CT 1-Step
TaqMan Kit (Ambion, Waltham, MA, USA) and TaqMan gene-expression
assays (Applied Biosystems, Foster City, CA, USA) according to manufac-
turers’ protocols (Appendix S1). Two RAD51C TaqMan gene-expression
assays that bind to exons 1 to 2 and 8 to 9 were used to measure RAD51C
expression and an ACTB assay was used as an endogenous control. The
reference sample was the unrelated non-carrier woman. The relative
expression was quantified using the comparative CT method. Four inde-
pendent experiments were performed with 3 technical PCR replicates.
Total RNA extracted with RNeasy Plus Mini kit (Qiagen, Hilden, Ger-
many) from 3 carrier and 2 control wild type lymphoblastoid cell lines
were subjected to reverse-transcription PCR with random primers using
the SuperScript III RT-PCR kit (Invitrogen, Waltham, MA, USA). Comple-
mentary DNA (cDNA) template was used for PCR. PCR was set up using
2 controls and 3 carrier lymphoblastoid cell lines cDNA, no template con-
trol, and human genomic DNA control (to confirm that PCR product is not
from genomic DNA). The templates were amplified using primers 50-CTA-
CACAGAGTTACTGGCAC-30 and 50-GTCCCAATGAAAGATTAGCCG-30
in RAD51C exons 4 and 7 or primers 50-CAGAACACTCAAAGGTTCGAC-
30 and 50-AGAGAAACCATCGTATGTTCC-30 in exons 4 to 5 junction and
intron 7. The PCR products were analyzed on agarose gel.
2.6 | Statistical analyses
Statistical analyses were performed by using the R version 3.0.2
(http://www.r-project.org/). To evaluate the difference in the fre-
quency of the duplication between cases and controls, 2-sided P-
values were calculated using Fisher's exact test. The difference in the
RAD51C expression was evaluated with Student's t test. A P-value
<.05 was considered statistically significant.
3 | RESULTS
3.1 | Mutations identified in the gene-panel testing
Out of the 95 patients tested with the gene-panel sequencing, 18 car-
ried clearly pathogenic mutations in the genes included in this study
(19%) (Tables 1 and 2). Altogether 12 different mutations were identi-
fied in these 18 patients (Table 1). Protein-truncating BRCA1 mutations,
including a large genomic change exon 13 duplication, were detected in
5 patients (5.3%) and BRCA2 mutations in 3 patients (3.2%). The CHEK2
c.1100delC mutation was detected in 7 patients (7.4%), 2 of which also
carried the CHEK2 splicing mutation c.444+1G>A. Further analysis of
family members showed that the 2 CHEK2 mutations were inherited in
different alleles in both of these patients. One pathogenic missense
mutation was identified in both the PTEN and TP53 genes. In RAD51C,
the Finnish founder mutation c.837+1G>A was observed in 1 patient
who was affected with ovarian and uterine cancer. No deleterious
mutations in STK11, PALB2, or RAD51D were detected. In addition to
these pathogenic mutations, the low-penetrance CHEK2 c.470T>C p.
Ile157Thr (I157T) missense variant was detected in 6 patients, 2 of
which were also BRCA1 carriers and 1 CHEK2 c.1100delC carrier.
Out of the 7 CHEK2 c.1100delC carriers, 6 were women diag-
nosed with breast cancer at an early age (range 22-39 years) and
1 was a male patient affected with breast and papillary thyroid can-
cers (Table 1). The PTEN mutation carrier was diagnosed with breast
cancer at the age of 39 and her mother and maternal aunt at the age
of 63 and 45. The maternal aunt was also diagnosed with synovial
sarcoma at the age of 43. After the result of the genetic test, the
patient was inspected more carefully. Her head circumference was
normal but she had a fibroma, goiter and several trichilemmomas.
The TP53 mutation carrier was diagnosed with bifocal breast cancer
at the age of 29. Her maternal grandfather's sister had breast cancer
at an old age and maternal aunt colon cancer at the age of 55. The
PTEN and TP53 mutations have been reported as pathogenic muta-
tions in the ClinVar (RCV000169787.2 and RCV000129010.2) and
HGMD databases and neither is observed in the ExAC database.
Pathogenic mutations were identified in 6 (17%) of the
35 patients from families with 3 or more affected members and in
5 (22%) of the 23 patients from families with 2 affected members
(Table 2). Of the early-onset breast cancer patients, 4 (22%) were
mutation positive whereas 20% of TNBC and male breast cancer
patients harbored mutations. Of the 20 patients from families previ-
ously tested negative for BRCA1/2 mutations, 1 harbored the CHEK2
c.1100delC and c.444+1G>A mutations and 1 had a BRCA1 nonsense
mutation which was not previously detected as only the BRCA1/2
founder mutations had been screened.
3.2 | Duplication of exons 1 to 7 in RAD51C
In addition to these 12 mutations detected in 18 patients, a novel
large heterozygous duplication encompassing the RAD51C exons 1 to
7 was observed in 1 patient. She was diagnosed with breast cancer at
the age of 40 and with basal cell carcinoma at the age of 45 and had
been previously tested negative for BRCA1/2 mutations. She also had
3 sisters affected with breast cancer. After Sanger sequencing, the
mutation was characterized as a 64 179 base pairs (bp) long duplica-
tion starting 31 512 bp upstream of the RAD51C start codon and
extending to the RAD51C intron 7 with a 10 bp insertion
CTTTTGTGAG between the copies (c.-31512_965+1210dup
{insCTTTTGTGAG} according to the extended HGVS nomenclature21)
(Figure 1). In effect, there is an extra copy of the upstream sequence
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and the RAD51C exons 1 to 7 located 31 kb upstream of the normal
copy of the RAD51C gene.
We screened the duplication with a PCR assay in the relatives of
the duplication carrier with available DNA samples (Figure S1). Two
of the index patient's 3 sisters affected with breast cancer were car-
riers whereas no duplications were observed in the 3 tested healthy
women. Other cancer cases in the family included ovarian cancer and
various other cancer types such as Hodgkin lymphoma, colorectal
cancer, and prostate cancer among distant relatives, but no samples
were available from these patients. We further genotyped the dupli-
cation in familial breast and ovarian cancer patients (n = 1149), in
unselected cohorts of breast (n = 1729) and ovarian (n = 553) cancer
TABLE 1 Pathogenic mutations observed in the 95 patients undergoing gene-panel testing
Mutationa Cancer (dg-age) Criterion Histologyb Grade ER PR HER2
BRCA1 c.3626delT BC (34) BC family ≥3 affected Ductal NA neg NA NA
BRCA1 c.3626delTc BC bilat (43 + 48) TNBC Ductal 3 neg neg neg
BRCA1 c.4656C>A p.Tyr1552Terc BC (52) and OC (58) BC + OC family 2 affected Ductal 1 pos pos NA
BRCA1 c.5278-1G>C BC (31) TNBC Ductal NA neg neg neg
BRCA1 c.4186-1787_4357
+4122dup (ex13 duplication)
BC bilat (54 + 54) BC + OC family ≥3 affected Ductal 3 neg neg neg
BRCA2 c.1286T>G p.Leu429Ter BC (38) Early-onset BC Ductal 3 neg neg pos
BRCA2 c.7480C>T p.Arg2494Ter BC (60) and OC (54) BC + OC family ≥3 affected Ductal NA pos neg neg
BRCA2 c.8314G>T p.Glu2772Ter BC (26) BC family 2 affected Ductal 2-3 pos pos pos
CHEK2 c.1100delCc BC (22) bifocal BC family 2 affected Ductal 3 pos pos pos
CHEK2 c.1100delC BC (34) BC family 2 affected Ductal 3 pos neg neg
CHEK2 c.1100delC BC (25) Early-onset BC Ductal 2 pos pos pos
CHEK2 c.1100delC BC (26) Early-onset BC Ductal 2 pos pos pos
CHEK2 c.1100delC BC (30) BC family ≥3 affected Ductal 3 pos neg pos
CHEK2 c.1100delC;
CHEK2 c.444+1G>A
BC bilat (39 + 69) BC family ≥3 affected Ductal 2 NA NA NA
CHEK2 c.1100delC;
CHEK2 c.444+1G>A
BC (46) and
thyroid (28)
MBC Ductal 2 pos pos neg
PTEN c.70G>T p.Asp24Tyr BC (39) BC family ≥3 affected Duct et lobular 3 pos pos neg
RAD51C c.837+1G>A OC (40) and
uterine (40)
BC + OC family 2 affected Serous 3 pos NA NA
TP53 c.844C>G p.Arg282Gly BC (29) bifocal Early-onset BC Ductal NA pos/neg pos/neg pos/pos
Abbreviations: BC, breast cancer; bilat, bilateral; dg-age, age at diagnosis; ER, estrogen receptor; MBC, male breast cancer; NA, not available; neg, nega-
tive; OC, ovarian cancer; pos, positive; PR, progesterone receptor; TNBC, triple-negative breast cancer.
Recurrent or founder mutations in the Finnish population are highlighted in bold.
a The coding refers to BRCA1 transcript NM_007294.3 (U14680.1 exon numbers), BRCA2 transcript NM_000059.3, CHEK2 transcript NM_007194.3,
PTEN transcript NM_000314.6, RAD51C transcript NM_058216.2 and TP53 transcript NM_000546.5.
b Tumor histology, grade, and ER, PR, and HER2 status is denoted for the first breast tumor except for the patient without breast cancer the information
is given for the ovarian tumor.
c Patient also carries the CHEK2 c.470T>C p.Ile157Thr variant.
TABLE 2 Number of mutation carriers in each patient group
Ascertainment criteria Total Mutation carriers (%)
Mutated genes (number of families with
mutations in the gene)
BC family ≥3 affected 35 6 (17%) BRCA1 (2), BRCA2 (1), CHEK2 (2), PTEN (1)
BC only (≥3 affected) 20 4 (20%) BRCA1 (1), CHEK2 (2), PTEN (1)
BC + OC (≥3 affected) 15 2 (13%) BRCA1 (1), BRCA2 (1)
BC family 2 affected 23 5 (22%) BRCA1 (1), BRCA2 (1), CHEK2 (2), RAD51C (1)
BC only (2 affected) 14 3 (21%) BRCA2 (1), CHEK2 (2)
BC + OC (2 affected) 9 2 (22%) BRCA1 (1), RAD51C (1)
Early-onset BC 18 4 (22%) BRCA2 (1), CHEK2 (2), TP53 (1)
TNBC 10 2 (20%) BRCA1 (2)
MBC 5 1 (20%) CHEK2 (1)
othera 4 0 (0%) —
All 95 18 (19%)
Abbreviations: BC, breast cancer; MBC, male breast cancer; OC, ovarian cancer; TNBC, triple-negative breast cancer.
a includes 3 BC and OC patients and 1 BC and colorectal cancer patient with a family history of other cancers.
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cases, and in healthy female population controls (n = 1273) collected
from the same geographic region. Seven additional duplication car-
riers were identified among cases and none among controls. Two of
them were familial breast cancer patients, 3 were unselected breast
cancer patients with 1 of them also affected with ovarian cancer, and
2 were unselected ovarian cancer patients. As RAD51C mutations
have been previously associated with ovarian cancer,9,16 we per-
formed subgroup analyses based on family history and personal his-
tory of breast and ovarian cancer in order to define the patient group
with the strongest association (Table 3). Altogether, half of the
8 duplication carriers were affected with ovarian cancer or had a fam-
ily history of ovarian cancer. The duplication was more frequent
among ovarian cancer cases (0.5%, P = .032) as well as among
patients with a personal or family history of ovarian cancer (0.5%,
P = .021) than among population controls (0.0%) (Table 3). The fre-
quency of the duplication among breast cancer patients was 0.2%
with a slightly higher 0.3% frequency among familial patients but did
not significantly differ from controls (P > .05). All the duplication car-
riers were negative for the Finnish RAD51C founder mutations
c.93delG and c.837+1G>A.
To investigate if the duplication is transcribed into mRNA and
whether it affects RAD51C expression we quantified the RAD51C
RNA levels in lymphoblastoid cell lines of 3 carriers and 2 non-car-
riers. We first measured the RAD51C expression with a probe binding
to RAD51C exons 1 to 2 boundary and used ACTB as an endogenous
control. Two of the duplication carriers showed significant, 1.52- to
1.68-fold, increased RAD51C expression compared with the non-
carrier control sample (P = .020 and P = .013) with the third carrier
showing 1.23-fold increase (P = .141) (Figure 2 and Table S1). On
average, the 3 carriers had 1.48-fold increased RAD51C expression
(P = .074 compared with the 2 non-carries). When the expression
was measured using a probe binding to exons 8 to 9 boundary, resid-
ing outside of the duplicated area, the expression levels of the car-
riers and non-carriers were comparable. When the RAD51C exons
8 to 9 probe was used as a control and the expression was measured
with the RAD51C exon 1 to 2 probe, the duplication carriers showed
1.21- to 1.66-fold increased expression, 1 of them with significantly
increased expression compared with the control (P = .006). On aver-
age, the 3 carriers had 1.42-fold expression of the RAD51C ex1-2
(P = .084 compared with the 2 non-carriers).
To further characterize the mRNA produced from the duplica-
tion, total RNA was extracted from lymphoblastoid cell lines of
3 duplication carriers and 2 wild type controls. If the translation con-
tinues into RAD51C intron 7, a new stop codon is predicted to appear
after 18 amino acids p.(Phe323SerfsTer18). Using a forward primer in
exon 4 and a reverse primer in exon 7, an expected 300 bp long
product was observed in both the controls and carriers (Figure S2).
When using a forward primer at the exon 4 to 5 junction and a
reverse primer in intron 7, a novel 663 bp long product was observed
in the carriers but not in the controls.
duplicated region chr17:56,738,493-56,802,671
c.-31512_965+1210dup{insCTTTTGTGAG}
full-length RAD51C geneRAD51C exons 1-7
Chr17
56,738,49356,802,671
Breakpoint:
G G A G T T A T T T T C T C C T T T TG TG A G T TG A G A T G C C
RAD51C intron 7 upstream
of RAD51C
10bp insertion
ex1 ex2ex3 ex4 ex5 ex6 ex7 ex
1 ex2ex3 ex4 ex5 ex6 ex7 ex8ex
9
FIGURE 1 Diagram of the RAD51C duplication which starts 31 kb upstream of the RAD51C gene and covers exons 1 to 7. The duplication is
highlighted in light red. Exon numbering is based on RAD51C transcript NM_058216.2 and the chromosome positions are according to build
hg19 (GRCh37)
TABLE 3 Frequencies of the RAD51C duplication among breast and
ovarian cancer patients and in different subgroups as defined by
family history and personal history of cancer
Patient group Total Wt (%) Dup (%) P-value
Population controls 1273 1273 (100.0%) 0 (0.0%)
All BCa 2533 2527 (99.8%) 6 (0.2%) .188
Unselected BC cohort 1729 1726 (99.8%) 3 (0.2%) .267
Familial BCb cohort 1187 1184 (99.7%) 3 (0.3%) .112
BC onlyc 973 971 (99.8%) 2 (0.2%) .188
BC + OCd 214 213 (99.5%) 1 (0.5%) .144
All OCe 590 587 (99.5%) 3 (0.5%) .032
Unselected OC cohort 553 551 (99.6%) 2 (0.4%) .092
Familial OCf 8 8 (100.0%) 0 (0.0%) 1
Any OCg 782 778 (99.5%) 4 (0.5%) .021
Abbreviations: BC, breast cancer; OC, ovarian cancer; dup, duplication
carrier; wt, wild type.
The patient groups are overlapping and described in more detail in
Appendix S1.
a All BC patients from the unselected and familial BC cohorts, 36 (includ-
ing 1 duplication carrier) are BC + OC patients included also in All OC.
b BRCA1/2-negative familial BC and BC + OC patients from the gene-
panel sequencing (n = 46) were combined with the genotyped patients
including also the patient where the duplication was discovered.
c BC families with no known family history of OC.
d BC families with at least 1 OC case among family members or distant
relatives.
e All OC includes unselected and familial OC patients and BC + OC
patients from the unselected and familial BC cohorts.
f OC patients with a family history of OC but not BC.
g Any OC includes all patients with personal or family history of OC.
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4 | DISCUSSION
The multigene panel testing of 95 high-risk breast or ovarian cancer
patients revealed pathogenic mutations in 18 patients (19%) and a
novel RAD51C ex1-7 duplication in 1 patient. While mutations in the
most important susceptibility genes BRCA1 and BRCA2 were
observed in 5.3% and 3.2% of the patients, respectively, the highest
mutation frequency of 7.4% was in CHEK2.
4.1 | Mutations in different patient groups and
characteristics of the mutation carriers
The only mutation observed in an ovarian cancer case not affected
with breast cancer was the RAD51C c.837+1G>A mutation while in
patients affected with both breast and ovarian cancer BRCA1 and
BRCA2 mutations were observed. This is consistent with an increased
risk of ovarian cancer but not breast cancer for RAD51C mutation
carriers and an increased risk of both breast and ovarian cancer for
BRCA1/2 mutation carriers.1,9,16 The 2 mutations detected among
the 10 patients ascertained because of TNBC were in BRCA1, con-
sistent with BRCA1 tumors being often triple-negative.22 CHEK2
mutations were detected in women diagnosed with breast cancer at
an early age and in a man diagnosed with breast and thyroid cancers.
This is in line with previous studies indicating that the relative breast
cancer risk of CHEK2 c.1100delC carriers decreases by age and show-
ing an association between CHEK2 mutations and the risk of male
breast cancer and thyroid cancer.23–26
Single PTEN and TP53 mutations were observed in patients who
did not present the most typical features of the PTEN hamartoma
tumor syndrome (PHTS) or Li-Fraumeni syndrome (LFS) caused by
germline mutation in these genes, respectively. PHTS is characterized
by macrocephaly, multiple hamartomas, and increased risks of malig-
nant and benign tumors, mainly of the breast, thyroid, and endome-
trium and LFS by a high risk and an early onset of cancer, most
commonly breast cancer, childhood sarcomas, brain tumors, and adre-
nocortical carcinoma.2–4 Interestingly, the identified PTEN mutation
carrier had features of Li-Fraumeni-like syndrome with an early-onset
breast cancer and a family history of breast cancer and sarcoma.
After the genetic test result, however, she was found to have a
fibroma, goiter and trichilemmomas typical for PHTS. The TP53 muta-
tion carrier had an early-onset breast cancer and a family history of
breast and colon cancer but did not fulfill the Chompret criteria for
TP53 testing.3 The detected PTEN and TP53 missense mutations have
been previously reported in PHTS and LFS families and the TP53
c.844C>G p.Asp24Tyr has been shown to function as a dominant
negative allele.27–29
4.2 | Double heterozygotes
Two patients carried 2 different protein-truncating mutations (2.1%
of the tested patients, 8.7% of the mutation carriers). In previous
gene-panel studies, Walsh et al observed 2 different mutations in
3 out of 360 unselected ovarian cancer patients (0.8% of tested,
3.7% of mutation carriers) and Tung et al in 5 out of 1781 breast can-
cer patients (0.3% of tested, 2.1% of mutation carriers).30,31 Carriers
of 2 mutations may have a higher risk than carriers of a single muta-
tion and low-penetrance variants may modify the risk of other muta-
tions. Both observed double heterozygotes in our study carried the
CHEK2 mutations c.1100delC and c.444+1G>A. In addition, 3 patients
with a truncating mutation in BRCA1 or CHEK2 carried the low-
penetrance CHEK2 missense c.470T>C. CHEK2 compound heterozy-
gotes have been estimated to have a higher risk of breast cancer than
women with a single CHEK2 mutation whereas a CHEK2 mutation in
a BRCA1 positive woman may not increase the risk beyond that of
the BRCA1 mutation alone.32 Moreover, 2 of the patients previously
tested negative for BRCA1/2 mutations were now found to harbor
either CHEK2 or BRCA1 mutations and a third patient carried the
RAD51C ex1-7 duplication. Lincoln et al compared traditional testing
with multigene panel testing and observed deleterious mutations in
other breast cancer genes in 2 patients previously tested negative for
the familial BRCA1/2 mutation and in 2 BRCA1/2 positive patients.33
Our results, together with other studies, highlight the advantage of
gene-panel testing as information for multiple genes is gained
simultaneously.
4.3 | RAD51C duplication
Two genomic changes were detected among the patients: the known
pathogenic BRCA1 exon 13 duplication and a novel 64 kb long dupli-
cation encompassing most of the RAD51C gene. The observed 0.5%
frequency of the RAD51C duplication among ovarian cancer patients
and its absence among population controls (P = .032) suggest an
increased risk of ovarian cancer, consistent with previous studies on
RAD51C.9,16 The cumulative risk of ovarian cancer by age 80 for
RAD51C mutation carriers has been estimated to be >9% whereas
there was no evidence for increased breast cancer risk (relative risk
[RR] = 0.91, P = .8).9 We have previously identified 2 recurrent
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deleterious RAD51C point mutations, c.93delG and c.837+1G>A, that
were each observed at a 0.5% frequency among unselected ovarian
cancer patients.16 This is comparable to the 0.4% duplication fre-
quency among unselected ovarian cancer patients. The RAD51C point
mutations increased the risk of ovarian cancer (odds ratio [OR] =
6.31, 95% confidence interval [CI]1.15-34.6, P = .033 for unselected
ovarian cancer cases compared with population controls) but did not
associate with breast cancer susceptibility in the absence of ovarian
cancer family history. It appears likely, that in RAD51C carrier families
with breast and ovarian cancer, there may be also other alleles con-
ferring increased breast cancer risk.
When combining the duplication and the point mutations, we
have observed 17 RAD51C mutation carriers among Finnish breast or
ovarian cancer patients with a combined frequency of 1.4% among
unselected ovarian cancer patients and 2.1% among patients with
personal or family history of ovarian cancer. The frequency is mark-
edly higher than a 0.32% RAD51C overall mutation frequency among
unselected ovarian cancer patients observed in a recent large
population-based study.34 This highlights the significance of recurrent
mutations in Finland.
In the ExAC database, a duplication encompassing the RAD51C
exons 1 to 7 has been observed in 12 of 3301 Finnish samples repre-
senting diverse population cohorts from different parts of the coun-
try. This CNV may represent the same duplication as observed here.
There are limitations of use of ExAC CNV data as variant calls and
frequency estimates are generated from targeted exome sequencing
with short reads, and rarity of events may compromise accurate fre-
quency estimates.35 However, due to the population history of Fin-
land, the allele frequencies differ between different geographical
regions and there are genetically distinct subisolates.36 Thus, geo-
graphical matching of cases and controls is important. In our study,
the population controls and the cases were collected from the same
geographical area. The ExAC CNV carriers may originate from a dif-
ferent region of Finland suggesting also that the detected RAD51C
CNV may be more prevalent in another part of the country. Further
validation of the association in larger datasets is warranted.
The identified duplication covers the first 7 exons of RAD51C
which are translated into amino acids 1 to 322 in the wild type pro-
tein. Assuming the translation continues into the intron 7, a new stop
codon is predicted after 18 amino acids p.(Phe323SerfsTer18). Con-
sistent with this, a novel mRNA isoform was observed in the duplica-
tion carriers. The heterozygous carriers have 3 copies of the RAD51C
exons 1 to 7 and 2 copies of the exons 8 to 9 in their genomes. This
is in line with the approximately 1.4-fold expression of the RAD51C
exons 1 to 2 compared with the exons 8 to 9 in the duplication car-
riers although the increase in expression compared with the non-
carriers did not reach statistical significance due to the small sample
size (P = .084). The results of the expression analysis suggest that a
stable aberrant mRNA may be produced. If the duplication is trans-
lated into a truncated protein, it might disturb the complex formation
of RAD51C. The RAD51C protein functions at DNA double-strand
break repair via homologous recombination and forms 2 distinct com-
plexes with the other RAD51 paralogs: the BCDX2 complex with
RAD51B, RAD51D, and XRCC2 and the CX3 complex with
XRCC3.37,38 The C-terminal amino acids 79 to 376 of RAD51C are
needed for the binding to RAD51B, RAD51D, or XRCC3 and a com-
plete β-sheet in the C-terminus is required for a proper folding of the
protein.39 Almost the entire RAD51C region, except for a few N-
terminal residues, may be needed for the XRCC3 binding.40 Thus, the
putative truncated RAD51C protein may not be able to bind the
other paralogs as it lacks the C-terminal amino acids that are critical
to binding. Besides the RAD51 paralogs, RAD51C also directly binds
to PALB2 and forms a complex with PALB2, BRCA2, and RAD51.41
Further functional studies are warranted to characterize the effect of
the duplication on the protein level and to establish the level of
pathogenicity.
In conclusion, the gene-panel testing of 95 high-risk breast or
ovarian cancer patients revealed 12 pathogenic BRCA1, BRCA2, TP53,
PTEN, CHEK2, or RAD51C mutations in 18 patients, with 2 patients
carrying more than 1 truncating mutation. The RAD51C ex1-7 dupli-
cation was identified as novel, likely pathogenic, recurrent mutation
in the Finnish population associating with the risk of ovarian cancer
and representing a large fraction of all identified RAD51C mutation
carriers. This data emphasizes the importance of comprehensive
mutation analysis of all the relevant genes simultaneously and includ-
ing a method to detect CNVs.
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